Diabetogen Biosciences Inc.
This article was originally published in Start Up
Diabetogen Biosciences' therapies target the autoimmune component of Type I diabetes and may help prevent onset of the disease.
You may also be interested in...
Many start-ups are developing diabetes drugs based on known targets which could attract Big Pharma partners and get to the clinic quickly, while a few invest in novel compounds that are either riskier or address the field's smaller subsets. Among the former are Phenomix, Plexxikon, CareX and Prosidion; among the latter are DiaKine, and DiaMedica. In all cases, these companies are looking to partner with Big Pharma, which is aggressively pursuing small-molecule drugs for diabetes.
The growing incidence of these diseases, and their complexity, provide opportunities for a number of different approaches
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.